Background Three biotherapies–etanercept, adalimumab and ustekinumab–are licensed in
childhood psoriasis. The few data available on their efficacy and tolerance are mainly …

This article provides comprehensive recommendations for the systemic treatment of severe
pediatric psoriasis based on evidence obtained from a systematic review of the literature …

Background Psoriasis is an immune-mediated inflammatory disease for which treatment has
evolved over the past few years due to the introduction of immunobiologic and small …

BACKGROUND: Evidence-based recommendations for therapeutic decision making in
childhood psoriasis are lacking. OBJECTIVES: We sought to systematically review all …

An advanced understanding of the pathogenesis of psoriasis has led to the development of
multiple therapeutic options for moderate-to-severe psoriasis. Tumor necrosis factor …

In 2008, a systematic review revealed that evidence‐based data on efficacy and safety of
treatments in paediatric psoriasis are scarce and with low level of evidence. In recent years …

Psoriasis is a chronic inflammatory systemic disease associated with an important physical
and physiological burden. It primarily affects the skin, but it is associated with several serious …

As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti‐tumor necrosis
factor‐α antibodies, became available in the field of dermatology in 2010, followed by …

Background: Psoriasis, an inflammatory disorder of the skin, can significantly impact on a
patient's quality of life, affecting their daily activities and families. The onset of psoriasis in …

The advent of biologic agents within the past two decades has dramatically improved the
treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved …